These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research]. Alván G Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017 [No Abstract] [Full Text] [Related]
3. [Europe for the development of pediatric drugs]. Combes G Soins Pediatr Pueric; 2002 Jun; (206):5-6. PubMed ID: 12140944 [No Abstract] [Full Text] [Related]
4. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role]. Ainsworth MA Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819 [TBL] [Abstract][Full Text] [Related]
5. [Marketing authorization for pharmaceuticals: the necessity of European collaboration]. Seitz R; Enzmann H Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):703-4. PubMed ID: 18592336 [No Abstract] [Full Text] [Related]
6. Positioning, labelling and control of medical information: artesunate strategy and Arsumax development story. Moneton P; Ducret JP Med Trop (Mars); 1998; 58(3 Suppl):70-2. PubMed ID: 10212905 [TBL] [Abstract][Full Text] [Related]
7. Getting SMART (submission management and review tracking) drug review in the computer age. Flieger K FDA Consum; 1995 Oct; 29(8):6-9. PubMed ID: 10151839 [TBL] [Abstract][Full Text] [Related]
8. Data protection: an anti-generic weapon. Prescrire Int; 2003 Dec; 12(68):235. PubMed ID: 14986701 [No Abstract] [Full Text] [Related]
11. A review of new drugs and indications in 2002: financial speculation or better patent care? Prescrire Int; 2003 Apr; 12(64):74-7. PubMed ID: 12674131 [TBL] [Abstract][Full Text] [Related]
12. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures]. Bachmann P Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780 [TBL] [Abstract][Full Text] [Related]
13. [EU law on marketing authorization of medicines. History, current state of development and perspectives]. Nettesheim M Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781 [TBL] [Abstract][Full Text] [Related]
14. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering? Purnhagen KP Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663 [No Abstract] [Full Text] [Related]
15. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase]. Kock M; Thomsen MK Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820 [TBL] [Abstract][Full Text] [Related]
16. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321 [TBL] [Abstract][Full Text] [Related]
17. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document]. Menges K Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104 [TBL] [Abstract][Full Text] [Related]
18. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure]. Enzmann H; Schneider C Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106 [TBL] [Abstract][Full Text] [Related]